Clinical trials: Allergy; Dermatitis
Dermatitis, Atopic
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
This study is being conducted to characterize the mechanism of action of crisaborole ointment 2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD) lesions treated with crisaborole ointment 2%…
- Trial name
- NCT03233529
- Testing
- Crisaborole ointment 2% BID
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan
Primary objective: To characterize the use patterns of phototherapy and immunosuppressants prior to dupilumab treatment for adult AD patients, who are eligible for dupilumab reimbursement in Taiwan (e.g., used regimens, reason…
- Trial name
- NCT05442645
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sanofi
Atopic Dermatitis
Characterisation of Skin Microstructure Under Normal and Atrophied States
Skin dermatoses are a major health concern around the world, with heavy economic, social, and psychological burdens. Due to their chronic and incurable nature, they are serious diseases that cause physical pain in patients and…
- Trial name
- COSMOS (NCT06954272)
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Atopic Dermatitis
Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?
It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called "non-specific effects" with the potential to affect sensitivity towards…
- Trial name
- NCT03142139
- Testing
- RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib, RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib, RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated
- Volunteers
- 1,027,559 people
- Sponsor
- Bandim Health Project
Atopic Dermatitis
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
This is a Phase II, randomized, double-blind, placebo-controlled multicenter study of repeated doses of MOR106 administered as IV infusion.
- Trial name
- IGUANA (NCT03568071)
- Testing
- MOR 106
- Where
- 53 sites in Germany, Hungary and 3 more
- Volunteers
- 207 people
- Sponsor
- Lakefront Biotherapeutics NV
Colorectal Cancer, Metastases
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
The study is a two-arm randomised phase III trial. Patients will be randomised to receive capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the investigator.
- Trial name
- SALTO (NCT01918852)
- Testing
- Capecitabine, Teysuno, Bevacizumab
- Where
- 24 sites in Netherlands
- Volunteers
- 161 people
- Sponsor
- Dutch Colorectal Cancer Group
Allergic Contact Dermatitis
Immune Reactions in Contact Dermatitis Affected Skin
This study hopes to improve the investigators understanding of how the immune system acts in allergic contact dermatitis. In order to reach this goal, normal volunteers, who are suspected of having allergic contact dermatitis…
- Trial name
- NCT01546298
- Testing
- Patch tests
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Eczema, Allergy
LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)
The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.
- Trial name
- NCT06584552
- Testing
- Lactobacillus Paracasei LPB27, Maltodextrin
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- The University of New South Wales
Allergic Rhinitis, Asthma
The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel
Ambrosia is known for its allergenicity in the USA causing hay fever and asthma. Israel has always been considered "clean" of Ambrosia but over the past years growth of Ambrosia plants has been detected in several locations in…
- Conditions
- Allergic Rhinitis, Asthma, Allergic Conjunctivitis, Atopic Dermatitis
- Trial name
- NCT01686048
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately.
- Trial name
- ZESTExt (NCT03948334)
- Testing
- ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
- Where
- 48 sites in United States, Belgium and 11 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Atopic Dermatitis, Skin Diseases
Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05469464
- Testing
- Orismilast modified release tablets
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 235 people
- Sponsor
- UNION therapeutics
Dermatitis, Atopic
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy of 611 in Chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT06173284
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 519 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis/Eczema
Atopic Dermatitis Adherence Study
Forgetting is usually listed as the most important cause of low adherence among patients. Most studies to date have looked at the adherence of adults or adolescent population.
- Trial name
- NCT02169986
- Testing
- electronic reminders
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Atopic Dermatitis
A Study of MG-K10 in Subjects With Atopic Dermatitis
This study evaluates the preliminary efficacy of MG-K10 in subjects with moderate to severe asthma, and provides a basis for the design and dosing regimen of phase III clinical trials.
- Trial name
- NCT05466877
- Testing
- MG-K10
- Where
- 2 sites in China
- Volunteers
- 163 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Allergic Contact Dermatitis
Reliability of Expired Allergens in Patch Testing: A Comparative Study With Non-Expired Series
Patch testing remains the gold standard in the diagnosis of allergic contact dermatitis. Patches used in testing consist of a wide spectrum of allergens, with variability in the stability of products over time.
- Trial name
- NCT07765563
- Testing
- Patch 1 (Expired), Patch 2 (non-expired)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of Calgary
Keloid, Tattoo
Tattooing and Piercing Among Medical Students
The aim of this study is to evaluate medical students' attitudes towards tattoos and piercings and to measure their awareness of associated dermatological risks.
- Conditions
- Keloid, Tattoo, Infection, Scar
- Trial name
- NCT07673484
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Biruni University
Atopic Dermatitis
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06397911
- Testing
- FB825
- Where
- 16 sites in United States, Taiwan
- Volunteers
- 114 people
- Sponsor
- Oneness Biotech Co., Ltd.
Atopic Dermatitis, Psoriasis
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
- Trial name
- NCT05718921
- Testing
- YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Asthma, Atrial Fibrillation
The Living With a Long-Term Condition Study
Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs).
- Conditions
- Asthma, Atrial Fibrillation, Cancer, Cerebrovascular Disorders
- Trial name
- LTC (NCT06072287)
- Testing
- Living with LTC Questionnaire
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- King's College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.